Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK

Géraldine Dominiak-Felden¹*, Catherine Cohet¹, Samantha Atrux-Tallau¹, Hélène Gilet², Amanda Tristram³ and Alison Fiander³

Abstract

Background: Data on the psychosocial burden of human papillomavirus (HPV)-related diseases other than cervical cancer are scarce. The objectives of this study were to measure and compare the psychosocial burden and the impact on health-related quality of life (HRQoL) of HPV-related lower genital tract diseases and genital warts (GW) using several generic and disease-specific instruments.

Methods: Overall, 842 individuals with normal cervical cytology (n = 241), borderline nuclear abnormalities and/or mild dyskaryosis (n = 23), cervical intraepithelial neoplasia (CIN)1 (n = 84), CIN2/3 (n = 203), vulval intraepithelial neoplasia (VIN)2/3 (n = 43), GW (n = 186) and a history of GW (non-current) (n = 62) were included. The generic European Quality of Life Index Version 5D (EQ-5D) questionnaire was completed by patients with GW and VIN2/3. Sexual functioning was evaluated using the Change in Sexual Functioning Questionnaire (CSFQ). Psychosocial impact was measured in women using the HPV Impact Profile (HIP) questionnaire. HRQoL was assessed using a GW-specific questionnaire, the Cuestionario Especifico en Condilomas Acuminados (CECA) (completed by patients with GW and history of GW). For each instrument, scores were compared between groups using the Student’s t-test. In addition, utility loss due to GW and VIN2/3 was evaluated by comparing mean EQ-5D scores weighted by age and sex with the UK general population normal values.

Results: A significant psychosocial impact was found in women diagnosed with HPV-related genital diseases, particularly in those with GW. The health state of younger adults with GW was significantly impaired compared with UK normal values (mean EQ-5D index score 0.86 vs 0.94, p < 0.001 for 18–24-year-olds; 0.87 vs 0.93, p = 0.030 for 25–34-year-olds). VIN2/3 was found to have a significant negative impact on sexual functioning, and women with VIN2/3 had a highly impaired health state compared with women in the UK general population (weighted mean EQ-5D index score 0.72 vs 0.89, p < 0.001; weighted mean Visual Analogue Scale score 62 vs 85, p < 0.001).

Conclusions: HPV-related lower genital tract lesions and GW significantly impair psychosocial wellbeing and HRQoL. The psychosocial aspects of HPV-related diseases need to be considered when evaluating the potential benefit of HPV vaccination.

Keywords: Cervical neoplasia, Genital warts, HPV, Vaccination, Vulval disease

* Correspondence: GDominiak-Felden@spmsd.com
1Department of Epidemiology, Sanofi Pasteur MSD, Lyon, France
Full list of author information is available at the end of the article

© 2013 Dominiak-Felden et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

Approximately 70% of sexually active individuals will be infected with human papillomavirus (HPV) during their lifetime [1]. Most infections are asymptomatic and clear spontaneously [2], but persistent infections with some HPV types may lead to anogenital neoplasia and genital warts (GW) [3,4].

The main burden of HPV-related diseases is due to cervical cancer. HPV-related precancerous lesions of the lower genital tract (e.g. cervical intraepithelial neoplasia [CIN] grades 1/2/3 and vulval intraepithelial neoplasia [VIN] grades 1/2/3) are also potentially serious conditions, requiring repeated health care visits for disease monitoring and treatment. Over the last 40 years, the incidence of VIN and vulval cancer has increased in developed countries, predominantly among women aged <50 years [5-8]. The incidence of GW has also increased considerably in many European countries, including the UK [9,10]. GW are unsightly and often cause discomfort, and only a minority of cases resolve without treatment. Treatment is usually lengthy and painful, and often does not prevent recurrences [3]. The increases in incidence of VIN, vulval cancer and GW may be partially explained by increased HPV transmission and infection rates due to changes in behaviour [11,12].

In Europe, two HPV genotypes (16 and 18) are responsible for approximately 73% of cervical cancers [13] and the majority of HPV-related vulval and vaginal cancers [14]. HPV 6 and 11 are responsible for 90% of GW affecting both men and women [3]. Primary prevention of HPV-related diseases through HPV vaccination is recommended in many countries. Two prophylactic HPV vaccines, Gardasil® (Sanofi Pasteur MSD, Lyon, France) and Cervarix® (GlaxoSmithKline Biologicals, Rixensart, Belgium), are available, which both protect against precancerous lesions, including CIN1/2/3, VIN2/3, and cervical cancer caused by HPV 16 and 18. In addition, the quadrivalent vaccine Gardasil® also protects against infection and disease caused by HPV 6 and 11, including GW. Determining the impact of HPV-related disease on patients’ health-related quality of life (HRQoL) is important to fully assess the value of HPV vaccination. Many studies have documented the psychosocial burden associated with cervical cancer and its impact on HRQoL [15-19] and some studies have evaluated the impact of GW [20-25]. However, fewer studies have quantified the impact of other HPV-related diseases [26-30] or used an HPV-specific questionnaire.

The objective of the Papillomavirus ASSociated QUALity of Life (PasQual) study was to assess the psychosocial burden and impact on HRQoL of HPV-related lower genital tract diseases and GW in the UK using generic and disease-specific instruments.

Methods

Participants

Study participants were aged 18–64 years and included women with normal cervical cytology, borderline nuclear abnormalities and/or mild dyskaryosis, CIN1, CIN2/3 and VIN2/3, and women and men with GW or with a history of GW. Participants included in the GW group were recruited any time during a current episode of GW (i.e. undergoing diagnosis and/or treatment of a GW episode that was clinically present at the time of inclusion in the study), whether this was a first episode or a recurrence. Participants included in the history of GW group were attending health care facilities for the follow-up of a previous sexually transmitted infection (STI) and had previously experienced an episode of GW that had resolved ≥6 months before study enrolment. Participants were made aware of their diagnosis and provided written informed consent prior to administration of questionnaires. Exclusion criteria included any concomitant STI, any concomitant condition that might have an impact on the psychosocial burden of participants, and vaccination with an HPV vaccine.

Study design and procedures

This was a multicentre, observational, cross-sectional study. Participants were recruited at 15 centres (six secondary care colposcopy and gynaecology clinics, five genitourinary medicine clinics, two general practice clinics and two family planning clinics) across the UK between May 2008 and March 2009.

The protocol and other study documents were approved by the Multi-Centre Research Ethics Committee for Wales (reference 07/MRE09/75), and local institutional approvals were obtained as appropriate. The study was conducted in accordance with the Declaration of Helsinki, Good Epidemiological Practice guidelines [31], and local regulations.

Basic demographic data, including age, sex, socioeconomic status, current marital/relationship status, medical history and clinical status, were collected at enrolment. Four instruments were used to measure the patient’s perspective: two disease-specific questionnaires (the HPV Impact Profile [HIP] questionnaire [32] and the Cuestionario Especifico en Condilomas Acuminados [CECA] [33,34] and two generic questionnaires (the European Quality of Life Index Version 5D [EQ-5D] [35] and the Change in Sexual Functioning Questionnaire [CSFQ] [36]). The instruments used in each HPV disease group are shown in Table 1.

The sample size calculation was based on the results of the US validation study for the HIP questionnaire [32], considering an anticipated response rate of 60% [37], a two-sided t-test with 90% power to detect a statistically significant difference in HIP scores between the
CIN group and the GW group at baseline, and study feasibility considerations. A sample of 50 participants with VIN2/3 and 200 in each of the other groups was defined.

**Patient-reported outcome instruments**

**HIP**
The HIP questionnaire is specifically designed to measure psychosocial burden in women with HPV-related diseases and comprises 29 items grouped into seven psychosocial dimensions: worries and concerns; emotional impact; sexual impact; self-image; partner issues and transmission; interactions with doctors; and health control and life impact [32]. Dimension scores and a total burden score, all ranging from 0 to 100, are calculated based on item scores. Higher scores indicate a greater psychosocial impact of HPV.

**CSFQ**
Short versions of the CSFQ, a validated, sex-specific questionnaire designed to measure the impact of diseases and medication on sexual functioning, were used [36], comprising 14 items grouped into five dimensions: pleasure, desire/frequency, desire/interest, arousal/excitement, and orgasm. Dimension scores and a total sexual functioning score are calculated as the sum of item scores. Lower scores indicate worse sexual functioning.

**EQ-5D**
The EQ-5D is a self-administered, generic, preference-based instrument designed to measure the impact of disease on the general health state, and comprises the EQ-5D index and the EQ Visual Analogue Scale (VAS) [35]. The EQ-5D index requires participants to state the extent of problems in five dimensions—mobility, self-care, usual activities, pain/discomfort and anxiety/depression—with a higher EQ-5D index score indicating a better general health state. The EQ VAS requires participants to rate their current state of health on a scale of 0–100, with 0 indicating the worst imaginable and 100 the best imaginable health state.

**CECA**
The CECA is a validated, ten-item, self-administered questionnaire designed specifically to measure the HRQoL of individuals with GW [33,34]. CECA items are grouped into two dimensions: emotional (six items) and sexual (four items); a global score is derived from the ten item scores. Scores range from 0 (worst HRQoL) to 100 (best HRQoL).

**Data analysis**
Women with normal cervical cytology were considered as the reference group against which women with HPV-related diseases were compared. As the CECA is specific to GW, healthy participants having never experienced GW are not able to answer the questionnaire and are not a suitable comparator. Therefore, in the assessment of CECA scores, participants with a history of GW were used as the reference group. The Student’s t-test (HIP, CSFQ and CECA) and analysis of variance (HIP and CSFQ) were used for between-group comparisons of questionnaire scores. Crude EQ-5D scores were described for participants with GW and participants with VIN2/3. Weighted mean EQ-5D scores were compared with UK general population normal values [38] using the Student’s t-test (data weighted according to the age/sex distribution of the UK population). Age-stratified comparisons of EQ-5D scores between participants with GW and UK general population norms were also conducted; due to low numbers of participants with VIN2/3, age stratified data for VIN2/3 are not presented. A p value ≤0.05 was considered statistically significant. All statistical analyses were performed using SAS software (version 9.1.3, SAS Institute, Inc., Cary, NC, USA).

| Table 1 Patient-reported outcome instruments used in each group |
|---------------------------------------------------------------|
| **Group** | **HIP** | **CSFQ** | **EQ-5D** | **CECA** |
| Normal cervical cytology | ✓ | ✓ | | |
| Borderline nuclear abnormalities and/or mild dyskaryosis | ✓ | ✓ | | |
| CIN1/2/3 | ✓ | ✓ | | |
| VIN2/3 | ✓ | ✓ | ✓ | |
| GW (women) | ✓ | ✓ | ✓ | ✓ |
| History of GW (women) | ✓ | ✓ | ✓ | ✓ |
| GW (men) | ✓ | ✓ | ✓ | ✓ |
| History of GW (men) | ✓ | ✓ | ✓ | |

CECA, Cuestionario Especifico en Condilomas Acuminados; CIN, cervical intraepithelial neoplasia; CSFQ, Change in Sexual Functioning Questionnaire; EQ-5D, European Quality of Life Index Version 5D; GW, genital warts; HIP, Human Papillomavirus Impact Profile; VIN, vulval intraepithelial neoplasia.

Ticks indicate that a given patient-reported outcome instrument was administered.
Results

Study population

Of the 2502 individuals screened for the PasQual study, 1512 (60.4%) met all the screening criteria and 1272 (50.8%) were included in the study after confirmation of diagnosis. Of these, 842 (66.2%) completed at least one item of one or more questionnaires. Patients with VIN2/3, GW and history of GW completed at least one item of the EQ-5D or the CECA (n = 290). Overall, numbers in each group were as follows: normal cervical cytology, n = 241; borderline nuclear abnormalities and/or mild dyskaryosis, n = 23; CIN1, n = 84; CIN2/3, n = 203; VIN2/3, n = 43; GW, n = 186; and history of GW, n = 62 (Figure 1). The mean age of study participants was 34 years (range 18–64 years); the socio-demographic characteristics of study participants are shown in Table 2.

Psychosocial burden assessment (HIP questionnaire)

Women with HPV-related disease had significantly higher mean total HIP scores than women with normal cervical cytology (Figure 2a, p < 0.001). Similar results were observed for all HIP dimensions (p ≤ 0.001, for all dimensions).

Sexual functioning assessment (CSFQ)

Women with HPV-related disease had similar mean total CSFQ scores compared with women with normal cervical cytology except for women with GW, who had significantly higher mean scores compared with women with VIN2/3 and women with a history of GW for the following dimensions: partner issues and transmission (58.7 [SD: 27.9] vs 46.9 [SD: 25.9], p = 0.012, for history of GW comparison); sexual impact (58.7 [SD: 27.9] vs 35.0 [SD: 25.8], p < 0.001, for history of GW comparison) and self-image (62.7 [SD: 22.9] vs 48.8 [SD: 22.9], p = 0.003, for VIN2/3 comparison).

Figure 1 Flow chart of study populations. CECA, Cuestionario Especifico en Condilomas Acuminados; CIN, cervical intraepithelial neoplasia; CSFQ, Change in Sexual Functioning Questionnaire; EQ-5D, European Quality of Life Index Version 5D; GW, genital warts; HIP, Human Papillomavirus Impact Profile; VIN, vulval intraepithelial neoplasia. * Of the 43 patients in the VIN2/3 group, one patient did not complete at least one item of the HIP/CSFQ questionnaires; a different patient did not complete at least one item of the CECA/EQ-5D questionnaires.
cytology, except women with VIN2/3 who had a significantly lower mean total CSFQ score (Figure 2b, p < 0.001). Mean dimension scores for women with HPV-related diseases were similar to those for women with normal cervical cytology, except for women with VIN2/3 who reported worse scores for pleasure, desire/frequency, desire/interest and arousal/excitement.

Participants with GW or a history of GW reported similar sexual functioning: mean total CSFQ score for women: 45.6 (SD: 8.3) vs 47.2 (SD: 7.3), p = 0.323; mean total CSFQ score for men: 50.3 (SD: 5.9 vs 49.6 (SD: 4.8), p = 0.637, for GW and history of GW, respectively.

QoL assessments

**EQ-5D**

**Analysis for women with VIN2/3** The mean crude EQ-5D index score was 0.74 (SD: 0.27) and mean crude VAS score was 66 (SD: 19.9) for women with VIN2/3. They reported problems with anxiety/depression (64%), pain/discomfort (45%), usual activities (29%), mobility (21%) and self-care (7%).

After weighting the data for the age distribution of the UK population, women with VIN2/3 had a significantly lower mean EQ-5D index score (0.72 [SD: 0.27] vs 0.89, p < 0.001) and mean VAS score (62 [SD: 18.9] vs 85, p < 0.001) than women in the UK general population. A significantly greater proportion of women with VIN2/3 reported problems with all dimensions of the EQ-5D index (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) compared with women in the UK general population, particularly for the anxiety/depression dimension (73% [95% confidence interval [CI]: 59.6–86.4] vs 21%, p < 0.001) (Figure 3a).

**Analysis for participants with GW** For women and men with GW, the mean crude EQ-5D index score was 0.84 (SD: 0.16) and 0.89 (SD: 0.17), respectively, and the mean crude VAS score was 75 (SD: 19.3) and 79 (SD:
Figure 2 Analysis of psychosocial burden and sexual function assessments (crude data, women only). (a) Comparison of mean total HIP scores. Higher scores indicate greater psychosocial impact. (b) Comparison of mean total CSFQ scores. Higher scores indicate better sexual functioning. p value is from analysis of variance. Borderline, borderline nuclear abnormalities and/or mild dyskaryosis; CIN, cervical intraepithelial neoplasia; CSFQ, Change in Sexual Functioning Questionnaire; GW, genital warts; HIP, Human Papillomavirus Impact Profile; Normal, normal cervical cytology; SEM, standard error of the mean; VIN, vulval intraepithelial neoplasia.

Figure 3 Comparison of EQ-5D health domains in participants with VIN2/3 and GW versus UK population norms (weighted data). (a) Percentage of women with VIN2/3 reporting some or extreme problems with EQ-5D dimensions compared with a sex-matched sample from the UK general population. p values are from χ² tests and compare the VIN2/3 group with the UK general population. (b) Percentage of participants (men and women) with GW reporting some or extreme problems with EQ-5D dimensions compared with the UK general population. p values are from χ² tests and compare the GW group with the UK general population. Error bars represent 95% confidence intervals. EQ-5D, European Quality of Life Index Version 5D; GW, genital warts; VIN, vulval intraepithelial neoplasia.
15.5), respectively. Problems reported by women were with anxiety/depression (41%), pain/discomfort (27%), mobility (7%), usual activities (4%) and self-care (2%). Men reported problems with anxiety/depression (25%), pain/discomfort (22%), usual activities (6%) and mobility (2%).

After weighting the data for the age and sex distribution of the UK population, participants with GW had a similar mean EQ-5D index score compared with the UK general population (0.90 [SD: 0.13] vs 0.89, p = 0.633), but a significantly lower mean VAS score (78 [SD: 14.8] vs 85, p < 0.001). Overall, a significantly higher proportion of participants with GW reported problems with anxiety/depression compared with the UK general population (41% [95% CI: 32.7–49.3] vs 19%, p < 0.001). By contrast, significantly lower proportions of participants with GW reported problems with mobility (4% vs 12%, p = 0.007) and usual activities (4% vs 12%, p = 0.005) compared with the UK general population (Figure 3b).

When age-stratified analyses were performed on crude data, the youngest participants with GW had significantly lower mean EQ-5D index scores compared with UK norms (0.86 vs 0.94, p < 0.001 for 18–24-year-olds and 0.87 vs 0.93, p = 0.030 for 25–34-year-olds). Evaluation of mean VAS scores by age showed a statistically significant difference versus UK norms in the younger age groups only (76 vs 86, p < 0.001 for 18–24-year-olds; 80 vs 87, p = 0.004 for 25–34-year-olds; and 75 vs 87, p = 0.050 for 35–44-year-olds).

**CECA**

Overall, participants with current GW had significantly lower mean CECA emotional, sexual and global scores than participants with a history of GW (non-current) (p = 0.008, p = 0.020 and p = 0.006, respectively; Figure 4a). After stratification by sex, similar differences were observed in women (Figure 4b) but not in men (Figure 4c).

**Discussion**

At the time that the PasQual study was implemented, no published study had simultaneously used several patient-reported outcome instruments in individuals with HPV-related diseases to capture the impact of these diseases from a patient's perspective. In the PasQual study, a significant negative psychosocial impact was found in women with a range of HPV-related diseases when compared with women with normal cervical cytology. Additionally, HPV-related external genital lesions (VIN2/3 and GW) were found to significantly impair HRQoL.

Differences in the age structure of the study groups reflected the epidemiology of the respective disease. The mean age of women with VIN2/3 was 45 years (range, 21–62 years). This is consistent with the fact that, historically, VIN2/3 and vulval cancer are associated with older age and long-term persistent infection with high-risk HPV, although both are now increasing in incidence in younger women [6]. By contrast, participants with GW or a history of GW had a mean age of 28 years (ranges, 18–60 and 19–52 years, respectively), reflecting the higher prevalence of GW in young adults than in older individuals [39].

The mean total HIP score for women with normal cervical cytology was 22.3, which was similar to mean total scores reported in the studies of Pirotta et al. (25.8) [40] and Wang et al. (28.2) [41], and about 8 points higher than that observed in the initial validation study for this instrument (14.4) [32]. The apparently elevated HIP scores for women with normal cervical cytology may indicate a negative impact of the cervical screening procedure itself, as observed in studies showing that women undergoing routine gynaecological examinations may experience pain or discomfort, embarrassment, fear, worry, nervousness and inconvenience [42,43]. However, in the absence of a defined scale linking scores to clinically relevant levels of impact, it is difficult to interpret absolute score values. In our study, women with normal cervical cytology were asked to complete the questionnaire when their test result was received. At this point, they were more likely to feel relieved and less likely to feel anxious than before receiving the result. Consequently, we consider that these women were a suitable reference group for the HIP questionnaire and CSFQ. In the absence of another adequate comparison group, men with a history of GW (non-current) were used as the reference group for men with current GW in analyses of the CSFQ.

Compared with women with normal cervical cytology, sexual functioning was significantly impaired only in women with VIN2/3, as assessed by the CSFQ. This finding may be partly related to age, as women with VIN2/3 tended to be older than participants in the other groups (mean age 44.8 vs 28.0–40.4 years, respectively). However, age is unlikely to be the only factor affecting sexual functioning. Women with VIN2/3 also had a highly impaired health state, as assessed by the EQ-5D index and VAS scores, compared with women in the UK general population, with particular detriments being observed in the anxiety/depression and pain/discomfort dimensions.

Women with current GW experienced the greatest negative psychosocial impact, as measured by the HIP questionnaire, while the impact was generally similar among women with other HPV-related diseases. These observations are consistent with reports of other studies that utilised the HIP questionnaire [32,40,41]. The mean total HIP score for women with current GW was 2.3-fold higher than the score for women with normal cervical cytology, which is consistent with the 1.8–3.7-fold
higher scores observed in women with GW versus normal cervical cytology in previous studies [32,40,41]. Dimensions that were particularly affected in women with GW were sexual impact, self-image, and partner issues and transmission. These dimensions have also been previously identified as being of particular concern in women with GW [40,44]. Wang et al. observed similar results for sexual impact and self-image, but there was also a substantial impact of GW on worries and concerns and less impact on partner issues and transmission [41]. It is particularly notable that the impact of GW on psychosocial burden appears to be greater than that of diseases such as VIN2/3, which are considered to be more severe from a clinical perspective and have been shown to have a significant impact on sexual functioning in previous studies [30,45]. The high psychosocial impact of GW may be because they are visible and distressing and associated with discomfort and feelings of anxiety, depression, anger, fear of contagiousness, shame and embarrassment [22,23,25,46]. In addition, treatment of GW is long, painful and often unsatisfactory, with high recurrence rates [3].

As assessed by the EQ-5D, participants with GW reported problems with anxiety/depression more frequently than the UK general population. This is consistent with current knowledge regarding the experience of individuals with GW in whom much of the associated morbidity is psychological in nature [25]. By contrast, a lower proportion of participants with GW in our study reported problems with mobility and usual activities than the UK general population. This latter observation is likely to be due to the age difference between the two populations as participants with GW were younger overall than the UK general population. The observed impact on the anxiety/depression dimension (41% of participants with GW reported problems) is similar to that reported in the recent study of Woodhall et al. [24], in which 37% of participants with GW reported problems in this dimension, and consistent with the findings of other studies [20,22,23]. However, contrary to our observations, three of these studies reported an increased level of pain/discomfort [22-24] and one study reported a detrimental impact on usual activities [22] among individuals with GW when compared with general population samples.

Overall, participants with GW had a slightly impaired health state, as assessed by the EQ VAS only, compared with the UK general population. However, when focusing on young adults (18–34 years of age), in whom the prevalence of GW is the highest, both the mean EQ-5D index and VAS scores were significantly reduced compared with the UK population norms. In our study, the weighted mean EQ-5D index and VAS scores for participants with GW were 0.90 and 78, respectively, which are similar to those reported for the recent study of

---

**Figure 4 Analysis of CECA scores (crude data).** (a) Comparison of mean CECA scores for male and female participants with GW versus those with a history of GW. (b) Comparison of mean CECA scores for women with GW versus those with a history of GW. Higher scores indicate a better health-related quality of life. p values are from the Student’s t-test and compare the GW group with the history of GW group. Error bars represent standard error of the mean. CECA, Cuestionario Especifico en Condilomas Acuminados; GW, genital warts.
Woodhall et al. (0.87 and 77, respectively) [24]. A significant reduction in health state based on EQ-5D index and VAS scores in individuals with GW when compared with general population values has been reported in other studies [22,23], in which the average reductions in EQ-5D index score were 3.9 and 9.9 percentage points, respectively, and the average reductions in VAS scores were 13.9 and 6.0 percentage points, respectively.

Participants with current GW had a significantly impaired HRQoL, as assessed by CECA scores, compared with participants with a history of GW (non-current). A similar but lesser impact of GW on HRQoL has been demonstrated in men in a study using the initial 22-item CECA questionnaire [47]. When stratified by sex in the present study, the difference between GW and history of GW continued to be observed in women, but not in men. In the PasQual study, female participants with GW had significantly lower scores for the sexual domain of the CECA than those with a history of GW, whereas sexual functioning as assessed by the CSFQ was similar between participants with GW and a history of GW. This may seem contradictory, but it is important to note that whilst the CECA evaluates the psychological aspects of sexual life specifically related to GW, the CSFQ is a generic instrument that evaluates functional aspects of sexual life, which may explain these differences.

Despite several measures taken to try and increase study recruitment (e.g. extension of study period and reminders sent to participants), sample sizes were lower than planned in some groups in our study. For participants with borderline nuclear abnormalities and/or mild dyskaryosis, CIN1 and a history of GW, actual sample sizes were 23, 84 and 62 respectively, compared with the 200 planned for each group. Several reasons may explain the low numbers, including that many women screened for participation in the CINI group did not have histological confirmation of CINI and were therefore not included, in the other two groups, few individuals complied with the retrospective recruitment process and, in addition, individuals with a history of GW recruited prospectively often had other STIs, which was an exclusion criterion.

As each HPV-related disease is associated with specific demographic characteristics, the UK general population may not have been the best comparator to evaluate the representativeness of our study population with regard to each specific disease. Differences in the mean age between different HPV disease groups may have partially impacted comparison across groups, particularly for sexual functioning. The older age of the VIN2/3 group compared with other groups may have impacted the comparison of sexual functioning assessed by the CSFQ. Furthermore, the younger age of the GW group compared with the reference group could have masked a potential negative impact of GW on sexual functioning.

For the CECA, participants with a history of GW were used as the reference group. Although this is not without limitations, we considered it to be the most appropriate comparator group as the CECA cannot be administered to individuals who have never experienced GW. The validation study for the CECA compared individuals with an initial diagnosis of GW with a group of individuals with persistent GW who were not receiving current treatment [34]. Furthermore, factors such as the number and size of lesions, which were measured in the validation study [34], were not considered in the current study. Finally, the study did not aim to collect clinical data. Thus, while we observed statistical differences in psychosocial burden and HRQoL between HPV disease groups, we could not assess the extent to which these differences were clinically meaningful.

Conclusions
This study demonstrates that HPV-related non-cancerous and precancerous genital disease have a significant negative impact on psychosocial wellbeing and HRQoL. The health state of younger adults with GW, in whom the prevalence of GW is known to be greatest, was significantly impaired compared with UK normal values. VIN2/3 was found to have a negative impact on sexual functioning and women with VIN2/3 had a highly impaired health state compared with women in the UK general population.

Abbreviations
CECA: Cuestionario Especifico en Condilomas Acuminados; CI: Confidence interval; CINI: Cervical intraepithelial neoplasia; CSFQ: Change in sexual functioning questionnaire; EQ-5D: European quality of life index version 5D; GW: Genital warts; HPV: Human papillomavirus; PasQual: Papillomavirus Associated QALity of Life; SF: Standard deviation; STI: Sexually transmitted infection; VAS: Visual analogue scale; VUL: Vulval intraepithelial neoplasia.

Competing interests
SA-T and GD-F are employed by Sanofi Pasteur MSD. CC was employed by Sanofi Pasteur MSD until November 2009. HG is an employee of Mapi, a consultancy company commissioned by Sanofi Pasteur MSD to assist with the statistical analysis and interpretation of results of the PasQual study. AF received an honorarium for attending advisory board meetings related to this study and received financial support from Sanofi Pasteur MSD for attendance at a conference where she presented the study results. She has received honoraria from Sanofi Pasteur MSD and GlaxoSmithKline for attending advisory board meetings, an honorarium from GlaxoSmithKline for participating in conference activities, and financial support from Sanofi Pasteur MSD, GlaxoSmithKline and Roche to attend HPV-related conferences. AT has received financial support from Sanofi Pasteur MSD for attendance at a conference where she presented the study results. She has received honoraria from Sanofi Pasteur MSD and GlaxoSmithKline for attending advisory board meetings, payment for lectures from GlaxoSmithKline and Sanofi Pasteur MSD (the Wales College of Medicine also received funding from these lectures), and financial support from GlaxoSmithKline, Sanofi Pasteur MSD and Roche to attend meetings. The Wales College of Medicine received an honorarium for AT to attend advisory board meetings related to this study.

Authors’ contributions
GD-F contributed to data analysis, participated in the interpretation of the study results, wrote the manuscript outline, and critically reviewed the manuscript drafts. CC was primarily involved in the design of the study, wrote the protocol, participated in the planning of statistical analyses,
contribution to data analysis for the cross-sectional component of the study, and critically reviewed the manuscript drafts. HG designed and performed the statistical analyses, participated in the interpretation of the study results, and critically reviewed the manuscript drafts. SA-T coordinated the study activities, validated the results and study report, and critically reviewed the manuscript drafts. AF was involved in developing the concept and design of the study, patient enrolment (patient data acquisition), obtaining regulatory approval, overseeing recruitment, and critically reviewing the manuscript drafts. AF was the Chief Investigator for the study and was involved in developing the concept and design of the study, had responsibility for obtaining regulatory approval and overseeing recruitment, contributed to data analysis and interpretation of the study results, and critically reviewed the manuscript drafts. All authors approved the final version of the manuscript.

Acknowledgments

Financial support for this study was provided by Sanofi Pasteur MSD. GD-F, CC and SA-T, who are employees of the sponsor, Sanofi Pasteur MSD, contributed to the design of study, data collection, analysis and interpretation and critical review of the manuscript (see Author contributions above). All authors were equally involved in the decision to submit the article for publication. The Wales College of Medicine was one of the study sites and received a grant from Sanofi Pasteur MSD to fund a research nurse to work on the study. It has also been a study site for an HPV vaccination study funded by GlaxoSmithKline. The authors take full responsibility for the content of this contribution and thank Communion Limited, Oxford, UK (supported by Sanofi Pasteur MSD) for their assistance in preparing the manuscript. All authors had full access to all of the data in the study and can take responsibility for the integrity of those data and the accuracy of the data analysis. The authors would like to thank the following: Andrew Nordin for his contribution to design of the study, data collection, analysis and interpretation of the study results, and critically reviewed the manuscript drafts. Andrew Nordin contributed to data analysis for the cross-sectional component of the study, patient enrolment (patient data acquisition), obtaining regulatory approval and overseeing recruitment, contributed to data analysis and interpretation of the study results, and critically reviewed the manuscript drafts. All authors approved the final version of the manuscript.

Guarantor for the study

Geraldine Dominiak-Felden.

Author details

1Department of Epidemiology, Sanofi Pasteur MSD, Lyon, France. 2Mapi, Lyon, France. 3Obstetrics and Gynaecology, Wales College of Medicine, Cardiff University, Cardiff, UK.

Received: 21 December 2012 Accepted: 31 October 2013 Published: 12 November 2013

References

1. Koutras L: Epidemiology of genital human papillomavirus infection. Am J Med 1997, 102:3–8.
2. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244–265.
3. Lacey CJN, Lowndes CM, Shah KV: Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006, 24(Suppl 3):S3–S41.
4. Wiertel U, Pfister H: Papillomavirus in human pathology: epidemiology, pathogenesis and oncogenic role. In Human Papillomavirus Infection: A clinical Atlas. Edited by Gross GE, Barraso R, Berlin: Ulstein Mosby; 1997:1–18.
5. Hamp M, Deckers-Figiel S, Hamp IA, Rein D, Bender HG: New aspects of vulvar cancer: changes in localization and age of onset. Gynecol Oncol 2008, 109:340–345.
6. Jones RH, Barillari L, Stables S: Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol 1997, 90:448–452.
7. Joura EA, Losch A, Häcker-Angeler MG, Breitenegger G, Leodolter S: Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med 2000, 45:613–615.
8. Judson PL, Habermann EB, Baxter NN, Durham SB, Vrign BA: Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006, 107:1018–1022.
9. Fenton KA, Lowndes CM: Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sex Transm Infect 2004, 80:255–263.
10. Health Protection Agency: STI Annual Data Tables. [http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/STIs/STIsAnnualDataTables/] Accessed 5-6-2013.
11. Hansen BT, Hagerup-Jenssen M, Kjær SK, Munk C, Tryggvadottir L, Sparen P, Liaw KL, Nygard M: Association between smoking and genital warts: longitudinal analysis. Sex Transm Infect 2010, 86:258–262.
12. Jones RW: Vulval intraepithelial neoplasia: current perspectives. Eur J Gynaecol Oncol 2001, 22:393–402.
13. Serrano B, Alenamy L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch FX, de S: Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012, 7:18.
14. Munoz N, Castellagliue X, de Gonzalez AB, Gismondo L: Chapter 1: HPV in the etiology of human cancer. Vaccine 2006, 24(Suppl 3):S13–S33.
15. Carver J, Sonoda Y, Baker RE, Ravli L, Chi DS, Barakat RR, Iasonos A, Brown CL, Abu-Rustum NR: A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer. Gynecol Oncol 2010, 119:358–365.
16. Greimel E, Winter R, Kapp KS, Haas J: Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psychooncology 2009, 18:746–482.
17. Herzog TJ, Wright JD: The impact of cervical cancer on quality of life—the components and means for management. Gynecol Oncol 2007, 107:572–577.
18. Kobayashi M, Ohno T, Noguchi W, Matsuda A, Matsushima E, Kato S, Tsuji H: Psychological distress and quality of life in cervical cancer survivors after radiotherapy: do treatment modalities, disease stage, and self-esteem influence outcomes? Int J Gynecol Cancer 2009, 19:1264–1268.
19. Korfage IJ, Essink-Bot ML, Mols F, Poll-Frame L, Kruitwagen R, van BM: Health-related quality of life in cervical cancer survivors: a population-based survey. Int J Radiat Oncol Biol Phys 2009, 73:1501–1509.
20. Maria C, Ogilvie G, Gastonguay L, Colley L, Taylor D, Maria F: Patients with genital warts have a decreased quality of life. Sex Transm Dis 2009, 36:258–260.
21. Mortensen GL, Larsen HK: The quality of life of patients with genital warts: a qualitative study. BMC Public Health 2010, 10:113.
22. Sénécal M, Brisson M, Maursell E, Ferenczy A, Franco EL, Ratnam S, Coutlee F, Paleyisk JM, Mansi JA: Loss of quality of life associated with genital warts: baseline analyses from a prospective study. Sex Transm Infect 2011, 87:209–215.
23. Woodhall S, Ramsey T, Cai C, Crouch S, Jit M, Birks Y, Edmunds WJ, Newton R, Lacey CJN: Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008, 84:161–166.
24. Sweeney JC, SC M, Soldan K, Fraser GD, Ross JD, Lacey CJN: The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect 2011, 87:458–463.
25. Ireland JA, Reid M, Powell R, Petrie KJ: The role of illness perceptions: psychological distress and treatment-seeking delay in patients with genital warts. Int J STD AIDS 2005, 16:667–670.
26. Likes WM, Stegbauer C, Tillmanns T, Pruett J: Pilot study of sexual function and quality of life after excision for vulvar intraepithelial neoplasia. J Reprod Med 2007, 52:23–27.
27. McFadden KM, Sharp L, Cruickshank ME: The prospective management of women with newly diagnosed vulval intraepithelial neoplasia: clinical outcome and quality of life. J Obstet Gynaecol 2009, 29:749–753.
28. Drolet M, Brisson M, Maunsell E, Franco EL, Coutlee F, Ferenczy A, Fisher W, Mansi JA: The psychosocial impact of an abnormal cervical smear result. Psychosocial Oncology 2012, 21:305–307.
29. Jayathunge MP, Bowanwatanuwong C, Maek A, Pitisuttithum BP: Psychosocial burden of abnormal pap smears among HIV-infected women at Chon Buri hospital, Thailand. Southeast Asian J Trop Med Public Health 2010, 41:224–234.
30. Likes WM, Stegbauer C, Tillmanns T, Pruett J: Correlates of sexual function following vulvar excision. Gynecol Oncol 2007, 105:650–653.
31. International Epidemiological Association (IAE): Good Epidemiological Practice (GEP): IEA guidelines for proper conduct in epidemiological research. 2007: http://ieaweb.org/2010/04/good-epidemiological-practice-gep/.
32. Mast TC, Zhu X, Demuro-Mercon C, Cummings HW, Sings HL, Ferris DG: Development and psychometric properties of the HPV Impact Profile (HIP) to assess the psychosocial burden of HPV. Curr Med Res Opin 2009, 25:2609–2619.
33. Badia X, Colombo JA, Lara N, Llorens MA, Olmos L, Sainz de los Terrenos M, Varela JA, Vilata JJ: Combination of qualitative and quantitative methods for developing a new Health Related Quality of Life measure for patients with anogenital warts. Health Qual Life Outcomes 2005, 3:24.
34. Vilata JJ, Varela JA, Olmos L, Colombo JA, Llorens MA, de los Terrenos MS, Badia X: Validation and clinical use of the CECA, a disease-specific quality of life questionnaire for patients with anogenital condylomata acuminata. Acta Derm Venereol 2008, 88:257–262.
35. The EuroQol Group: EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:191–208.
36. Keller A, McCarney R, Clayton AH: Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). J Sex Marital Ther 2006, 32:43–52.
37. French DP, Maisey E, Marteau TM: Psychological costs of inadequate cervical smear test results. Br J Cancer 2004, 91:1887–1892.
38. Kind P, Hardman G, Macran S: UK population norms for EQ-5D. Discussion paper 172. 1999. University of York Centre for Health Economics. [http://www.york.ac.uk/media/che/documents/papers/discussionpapers/CH%20DiscussionPaper%20172.pdf]. Accessed 12-1-2012.
39. Kraut AA, Schink T, Schulze-Rath R, Mikołajczyk RT, Garbe E: Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis 2010, 10:560.
40. Pirrota M, Ung L, Stein A, Conway EL, Mast TC, Fairley CK, Garland S: The psychosocial burden of human papillomavirus related disease and screening interventions. Sex Transm Infect 2009, 85:508–513.
41. Wang KL, Jeng CJ, Yang YC, Chen CA, Cheng WF, Chen TC, Mast TC, Wang YC, Hsieh CY: The psychological impact of illness among women experiencing human papillomavirus-related illness or screening interventions. J Psychosom Obstet Gynaecol 2010, 31:16–23.
42. Cullen J, Schwartz MD, Lawrence WF, Selby IV, Mandelblatt JS: Short-term impact of cancer prevention and screening activities on quality of life. J Clin Oncol 2004, 22:943–952.
43. Kahn JA, Chiou V, Allen JD, Goodman E, Perlman SE, Emans SJ: Beliefs about Papanicolaou smears and compliance with Papanicolaou smear follow-up in adolescents. Arch Pediatr Adolesc Med 1999, 153:1046–1054.
44. Drolet M, Bissinon M, Maunsell E, Franco EL, Coutlee F, Ferenczy A, Ratnam S, Fisher W, Mansi JA: The impact of anogenital warts on health-related quality of life: a 6-month prospective study. Sex Transm Dis 2011, 38:949–956.
45. Shylasree TS, Karanggaokar V, Tristram A, Wilkes AR, Maclean AB, Fandey AN: Contribution of demographic, psychological and disease-related factors to quality of life in women with high-grade vulval intraepithelial neoplasia. Gynecol Oncol 2008, 110:185–189.
46. Clarke P, Ebel C, Catotti DN, Stewart S: The psychosocial impact of human papillomavirus infection: implications for health care providers. Int J STD AIDS 1996, 7:197–200.
47. Dediol I, Buljan M, Vurnek A, Ubrilovia A: Psychological burden of anogenital warts. J Eur Acad Dermatol Venereol 2009, 23:1035–1038.